Clinical trials: Dementia
Alzheimer Disease, Dementia
A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation
The goal of this Phase 2 Alzheimer's study is to determine whether 1.0 mg/kg XPro1595 confers a benefit on cognition, function, and biomarkers of white matter and to further evaluate safety and tolerability.
- Conditions
- Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
- Trial name
- MINDFuL (NCT05318976)
- Testing
- XPro1595
- Where
- 41 sites in Australia, Canada and 6 more
- Volunteers
- 207 people
- Sponsor
- Inmune Bio, Inc.
Alzheimer's Disease
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease
This study in individuals with early Alzheimer's disease is designed to assess:(1) safety and tolerability (2) the capacity of ACC-001 and QS-21 adjuvant to reduce brain amyloid load as measured by positron emission tomography…
- Trial name
- NCT01227564
- Testing
- ACC-001 3 μg/ QS-21 50 μg, ACC-001 10 μg/ QS-21 50 μg
- Where
- 40 sites in United States
- Volunteers
- 63 people
- Sponsor
- Pfizer
Dementia of Alzheimer's Type
A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type
This is a Phase II, ascending dose study of CPC-201 in patients with dementia of Alzheimer's type to determine the optimal dose titration schedule.
- Trial name
- CPC-12 (NCT02549196)
- Testing
- Donepezil, Solifenacin
- Where
- 4 sites in United States
- Volunteers
- 28 people
- Sponsor
- Chase Pharmaceuticals Corporation, an affiliate of Allergan plc
Agitation Associated With Bipolar Disorder, Agitation,Psychomotor
Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder
This is a definitive study to support the safety and efficacy evaluation of BXCL501 for the acute treatment of agitation in bipolar disorder.
- Conditions
- Agitation Associated With Bipolar Disorder, Agitation,Psychomotor, Bipolar Disorder
- Trial name
- SERENITY II (NCT04276883)
- Testing
- Sublingual film containing Dexmedetomidine (BXCL501)
- Where
- 15 sites in United States
- Volunteers
- 380 people
- Sponsor
- BioXcel Therapeutics Inc
Alzheimer's Disease
Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate Alzheimers
This is a Phase III, multicenter, open-label extension, single-group study in male and female outpatients with mild-to-moderate Alzheimer's disease (AD) who have completed AVA105640.
- Trial name
- NCT00550420
- Testing
- Rosiglitazone XR
- Where
- 70 sites in United States, Austria and 16 more
- Volunteers
- 331 people
- Sponsor
- GlaxoSmithKline
Palliative Care, Dementia
Implementation of a Telehealth Palliative Care Model for Persons With Dementia
Grounded in the Reach-Effectiveness-Adoption-Implementation-Maintenance (RE-AIM) Model, this study will assess the implementation outcomes of the Nurse Practitioner (NP) delivered telehealth Palliative Care Consultation in…
- Trial name
- IMPACT (NCT05001620)
- Testing
- Palliative Care Consultation
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Alzheimer's Disease, Aphasia
Effect of Repetitive Transcranial Magnetic Stimulation on Language in Alzheimer's Disease
The investigators wish to investigate the efficacy of targeted repetitive transcranial magnetic stimulation (rTMS) on expressive language in patients with Alzheimer's disease (AD).
- Conditions
- Alzheimer's Disease, Aphasia, Dementia
- Trial name
- NCT00814697
- Testing
- Repetitive Transcranial Magnetic Coil Stimulation (rTMS)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- The New York Memory Services
Alzheimer Disease, Cognitive Dysfunction
A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease
The primary purpose of this study is to evaluate the effect of JNJ-63733657 versus placebo on clinical decline as measured by the Integrated Alzheimer's Disease Rating Scale (iADRS), a composite of cognition and function.
- Conditions
- Alzheimer Disease, Cognitive Dysfunction, Dementia
- Trial name
- Autonomy (NCT04619420)
- Testing
- JNJ-63733657
- Where
- 122 sites in United States, Australia and 8 more
- Volunteers
- 523 people
- Sponsor
- Janssen Research & Development, LLC
Huntington Disease
Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease
WVE-HDSNP2-002 is an open-label extension (OLE) study to evaluate the safety, tolerability, PK, PD, and clinical effects of WVE-120102 in adult patients with early manifest HD who carry a targeted single nucleotide polymorphism…
- Trial name
- NCT04617860
- Testing
- WVE-120102
- Where
- 20 sites in Australia, Canada and 5 more
- Volunteers
- 36 people
- Sponsor
- Wave Life Sciences USA, Inc.
Dementia, Depression
Pilot Study to Examine Health Effects of Daylight Exposure on Dementia Patients
This study is designed to test the hypothesis that an intervention increasing exposure to daylight indoors will reduce depression and other neuropsychiatric symptoms among people living with dementia in long term care facilities.
- Conditions
- Dementia, Depression, Behavior Disorders
- Trial name
- NCT03483896
- Testing
- Daylight Intervention
- Where
- 8 sites in United States
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Alzheimer Disease, Mild Cognitive Impairment
Brain Energy for Amyloid Transformation in Alzheimer's Disease Study
The Brain Energy for Amyloid Transformation in AD (Alzheimer's disease) or BEAT-AD study will compare the effects of a ketogenic low-carbohydrate diet and a low-fat diet in adults with mild cognitive impairment.
- Trial name
- BEAT-AD (NCT03472664)
- Testing
- low carbohydrate/high fat diet, low fat/high carbohydrate diet
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Wake Forest University Health Sciences
Alzheimer Disease
A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly Volunteers
A preliminary study to test how florbetapir F 18 (18F-AV-45) acts in the brains and bodies of healthy elderly people and patients with Alzheimer's Disease (AD) by using a positron emission tomography (PET) scanner.
- Trial name
- NCT01565291
- Testing
- florbetapir F 18
- Where
- 3 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Dementia With Lewy Bodies (DLB)
A Long-term, Extension Study of E2020 in Patients With Dementia With Lewy Bodies
The purpose of this study is to evaluate the safety and efficacy of E2020 in patients with Dementia with Lewy Bodies (DLB).
- Trial name
- NCT00598650
- Testing
- E2020
- Volunteers
- 160 people
- Sponsor
- Eisai Co., Ltd.
Mild Cognitive Impairment, Major Depressive Disorder
Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment
Alzheimer's disease (AD), the most common dementing disorder of later life, is a major cause of disability and death in the elderly. Although a number of theoretical causes exist, the etiology of AD is still unknown.
- Conditions
- Mild Cognitive Impairment, Major Depressive Disorder, Alzheimer's Disease
- Trial name
- NCT01876823
- Testing
- es-citalopram, Memantine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- New York State Psychiatric Institute
Alzheimer Disease, Dementia
STAR Caregivers - Virtual Training and Follow-up
This study evaluates the effectiveness of a caregiver outreach, training, and support program for caregivers of people with dementia who are using antipsychotic medication to manage agitation/aggression.
- Conditions
- Alzheimer Disease, Dementia, Caregiver Burnout
- Trial name
- STAR-C-VTF (NCT04271046)
- Testing
- STAR-C-VTF, Control
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- Kaiser Permanente
Dementia, Dementia, Vascular
Palliative Care for Persons With Late-stage Alzheimer's and Related Dementias and Their Caregivers
Millions of Americans have late-stage Alzheimer's and related dementias (ADRD), causing suffering due to loss of awareness of self and family, progressive dependency, physical and neuropsychiatric symptoms, and physical…
- Conditions
- Dementia, Dementia, Vascular, Dementia With Lewy Bodies, Dementia Frontal
- Trial name
- ADRD-PC (NCT04948866)
- Testing
- ADRD-PC Program
- Where
- 5 sites in United States
- Volunteers
- 884 people
- Sponsor
- University of North Carolina, Chapel Hill
Alzheimer Disease, Mild Cognitive Impairment
Brain Energy Metabolism and Sleep in Adults
The three primary goals of this pilot will be followed by a secondary goal to test if dental intervention improves brain health in terms of sleep and cognition. The primary and secondary goals are 1.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Cognitive Change, Energy Metabolism
- Trial name
- NCT03929302
- Testing
- MyTAP oral appliance plus mouth shield
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- The University of Texas at Dallas
Alzheimer's Disease
Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease
This is a multi-center, open-label, single-arm, prospective, phase IV trial, evaluating safety and efficacy of donepezil hydrochloride in patients with moderate to severe Alzheimer's disease.
- Trial name
- SAVE (NCT02097056)
- Testing
- Donepezil HCL
- Where
- 13 sites in South Korea
- Volunteers
- 171 people
- Sponsor
- Eisai Korea Inc.
Alzheimer Disease
A Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease
This is a randomized, double-blind, placebo-controlled, parallel-group comparison study in subjects with Alzheimer's Disease. Following first screening period, subjects will be randomly assigned into one of the following arms…
- Trial name
- NCT03117738
- Testing
- AstroStem
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Nature Cell Co. Ltd.
Huntington Disease
Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease
WVE-HDSNP1-002 is an open-label extension (OLE) study to evaluate the safety, tolerability, PK, PD, and clinical effects of WVE-120101 in adult patients with early manifest HD who carry a targeted single nucleotide polymorphism…
- Trial name
- NCT04617847
- Testing
- WVE-120101
- Where
- 18 sites in Australia, Canada and 5 more
- Volunteers
- 27 people
- Sponsor
- Wave Life Sciences USA, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.